Phase II Study of TAS-106 to Treat Head and Neck Cancer

• Status: Terminated
• Trial end date: 2012-02-01
• Target enrollment: 0
• Participant gender: All

Summary

The purpose of this study is to determine whether TAS-106 is effective to patients with recurrent or metastatic head and neck cancer refractory to platinum based chemotherapy.

• Phase: Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Taiho Pharmaceutical Co., Ltd.

Criteria

Inclusion Criteria:

• Age 18 ≤ years old at study entry

• Histologically confirmed head and neck carcinoma

• Received prior platinum based regimen and developed disease progression or recurrence

• Measurable disease according to RECIST guidelines

Exclusion Criteria:

• Radiological or clinical evidence of brain involvement or leptomeningeal disease

• ≥ grade 2 peripheral neuropathy

• History of another malignancy